Trade Alert: The Independent Director Of Athira Pharma, Inc. (NASDAQ:ATHA), Grant Pickering, Has Just Spent US$60k Buying 3,193% More Shares

·3 min read

Whilst it may not be a huge deal, we thought it was good to see that the Athira Pharma, Inc. (NASDAQ:ATHA) Independent Director, Grant Pickering, recently bought US$60k worth of stock, for US$2.41 per share. While that isn't the hugest buy, it actually boosted their shareholding by 3,193%, which is good to see.

View our latest analysis for Athira Pharma

The Last 12 Months Of Insider Transactions At Athira Pharma

Over the last year, we can see that the biggest insider purchase was by Chief Financial Officer Glenna Mileson for US$142k worth of shares, at about US$2.85 per share. So it's clear an insider wanted to buy, even at a higher price than the current share price (being US$2.50). It's very possible they regret the purchase, but it's more likely they are bullish about the company. To us, it's very important to consider the price insiders pay for shares. It is generally more encouraging if they paid above the current price, as it suggests they saw value, even at higher levels.

Over the last year, we can see that insiders have bought 125.00k shares worth US$359k. But they sold 20.00k shares for US$54k. In the last twelve months there was more buying than selling by Athira Pharma insiders. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!


There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

Does Athira Pharma Boast High Insider Ownership?

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. We usually like to see fairly high levels of insider ownership. Our data suggests Athira Pharma insiders own 1.3% of the company, worth about US$1.3m. I generally like to see higher levels of ownership.

So What Does This Data Suggest About Athira Pharma Insiders?

The recent insider purchases are heartening. We also take confidence from the longer term picture of insider transactions. But we don't feel the same about the fact the company is making losses. We would certainly prefer see higher levels of insider ownership but analysis of the insider transactions suggests that Athira Pharma insiders are expecting a bright future. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Athira Pharma. Be aware that Athira Pharma is showing 4 warning signs in our investment analysis, and 2 of those are concerning...

But note: Athira Pharma may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at)

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here